#USA #Chicago #Bridge to Life #VitaSmart™ #Medica S.p.A

Bridge to Life Expands Organ Preservation Innovations

Bridge to Life Ltd., an influential player in organ preservation solutions, has announced a significant acquisition that promises to advance transplant medicine. The company has purchased the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.. This acquisition not only includes exclusive global branding rights but also provides the opportunity to register the VitaSmart™ name internationally.

This strategic move marks a milestone in Bridge to Life’s continuous efforts to improve transplantation methodologies. The user-friendly design of the VitaSmart™ system, combined with its minimal monitoring requirements, is anticipated to be a game changer in organ preservation processes. More than 5,000 successful liver perfusions have been documented utilizing hypothermic oxygenated perfusion (HOPE) alongside the VitaSmart™ system, showcasing its effectiveness.

Don Webber, the CEO and President of Bridge to Life, expressed enthusiasm over this acquisition. He underscored the system's capacity to facilitate the adoption of HOPE protocols for European clinicians. Webber stated, "We are thrilled to now own the VitaSmart™ technology, which will allow us to advance our mission in organ preservation while making significant strides in transplant outcomes."

Furthermore, the company disclosed that they are nearing the finalization of an FDA application for the VitaSmart™ system, aimed for submission in the first quarter of 2025. It was noted that the results from their one-year patient follow-up in a pivotal US study have yielded impressive clinical outcomes, highlighting significant advantages for early allograft dysfunction and reduced hospital stays post-transplantation.

This acquisition not only strengthens Bridge to Life’s organizational value but also expands access to this innovative technology for transplant centers and organ procurement organizations across the United States. As patients eagerly await viable liver transplants, the implications of this strategic move could enhance patient care and outcomes significantly.

The acquisition aligns seamlessly with Bridge to Life's mission of enhancing transplant outcomes and ultimately saving more lives. The firm’s robust portfolio, which includes established products such as the Belzer UW® and EasiSlush®, places it at the forefront of the organ preservation market.

About Medica S.p.A.

Medica S.p.A. is a renowned Italian biomedical and MedTech company headquartered in the biomedical district of Mirandola, Italy. Known for its commitment to providing technologically advanced products for blood and water purification, Medica operates with a strong international presence.

About Bridge to Life Ltd.

Bridge to Life Ltd. is a leader in organ preservation, offering top-tier products to premier transplant centers and organ procurement organizations worldwide. With a strong emphasis on innovation, product quality, and accessibility, Bridge to Life continues to push the boundaries in organ preservation technology.